JFL Life Sciences Limited

As of March 31, 2026, JFL Life Sciences Limited carries a market capitalization of 282.11M, placing it among publicly traded companies globally. Its enterprise value stands at 484.53M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, JFL Life Sciences Limited has 33.00M shares outstanding.

As of March 31, 2026, JFL Life Sciences Limited trades at a trailing price-to-earnings ratio of 4.41. The price-to-sales ratio is 0.21, and the price-to-book ratio stands at 0.62.

As of March 31, 2026, JFL Life Sciences Limited trades at an EV/EBITDA multiple of 4.14 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.37 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 4.56 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 484.53M versus a market cap of 282.11M, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, JFL Life Sciences Limited maintains a current ratio of 1.73, meaning it holds 1.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 47.37, indicating elevated leverage, while an interest coverage ratio of 5.95 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended March 31, 2026, JFL Life Sciences Limited posted a return on equity (ROE) of 15.00, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 12.76 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 7.19, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 13.37, useful for judging operating efficiency across full business cycles. Inventory turnover of 3.98 indicates how many times JFL Life Sciences Limited sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, JFL Life Sciences Limited recorded 21.98M in income tax expense. That works out to an effective tax rate of 25.56, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 85.99M, leaving 64.01M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, JFL Life Sciences Limited's stock has declined approximately 16.26% over the past 52 weeks. The 50-day moving average sits at 11.24, while the 200-day moving average is 10.95.

Over the twelve months ended March 31, 2026, JFL Life Sciences Limited generated 1.31B in revenue and converted that into 64.01M in net income, yielding earnings per share of 1.94. EBITDA reached 117.11M, while operating income came in at 106.36M.

As of March 31, 2026, JFL Life Sciences Limited holds 14.87M in cash and equivalents against 217.29M in total debt, resulting in a net debt position of 208.66M. Total book value stands at 458.69M, with working capital of 385.12M providing operational flexibility.

JFL Life Sciences Limited produced -43.31M in operating cash flow over the twelve months ended March 31, 2026. After subtracting -33.78M in capital expenditures, free cash flow totaled -77.09M - equivalent to -2.34 per share.

Over the twelve months ended March 31, 2026, JFL Life Sciences Limited posted a gross margin of 12.48, reflecting its pricing power and cost economics. The operating margin of 8.10 and net profit margin of 4.87 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2026. Free cash flow yield is negative at -27.33: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -32.27, meaning JFL Life Sciences Limited raised more capital through share issuance and new debt than it returned via dividends and buybacks.

JFL Life Sciences Limited's most recent stock split took place on October 8, 2024 with a 1:3 split ratio.

As of March 31, 2026, JFL Life Sciences Limited has an Altman Z-Score of 2.45, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.